About oncolytic viruses

Oncolytic viruses (OVs) specifically replicate in tumor cells and cause cell lysis without harming healthy normal cells.

Technological advances in molecular virology have made it possible to engineer the viral genome to arm the virus with therapeutic gene(s). This 'armed' OV can remove tumor-induced immunosuppression and drastically modify the tumor microenvironment to enhance therapeutic efficacy.

Current oncolytic viruses (OVs) are usually attenuated, possessing limited clinical efficacy and often designed only for intratumoral delivery.


1.     Virogin's next generation OVs are built on an innovative technology named Transcription and Translation Dual Regulation (TTDR), which ensures high tumor specificity and efficacy without attenuation of the virus.

2.     Virogin’s Synerlytic™ platform creates a powerful synergy between robust oncolysis and multiple immune regulatory factors released by the virus.